Jan. 16, 2020 -- The prescription weight control medicine lorcaserin (Belviq, Belviq XR) may increase the risk of cancer, according to the results of a clinical trial assessing the safety of the drug, the U.S. Food and Drug Administration says.
The agency said "we cannot conclude that lorcaserin contributes to the cancer risk," but "wanted to make the public aware of this potential risk. We are continuing to evaluate the clinical trial results and will communicate our final conclusions and recommendations when we have completed our review."
Health care providers should weigh the benefits of taking lorcaserin against the potential risks when deciding whether to prescribe or continue patients on the medication, the FDA advised.
It said that patients currently taking lorcaserin should talk to their health care professionals about the potential increased risk of cancer with use of the medication.
Lorcaserin increases feelings of fullness so that people eat less. It's available as a tablet (Belviq) and an extended-release tablet (Belviq XR).